Cancer Monoclonal Antibodies Industry, Forecast to 2025 - Data on Bevacizumab, Rituximab, Trastuzumab, Cetuximab, Panitumumab and Others

DUBLIN, May 5, 2020 /PRNewswire/ -- The "Cancer Monoclonal Antibodies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

The global cancer monoclonal antibodies market is currently witnessing strong growth. Looking forward, the market is expected to grow at a CAGR of more than 10% during 2020-2025.

The increasing prevalence of cancer across the globe is one of the key factors driving the growth of the market. In comparison to traditionally used non-targeted therapies, such as chemotherapy, monoclonal antibodies have reduced side-effects on the patient's body and can also be used for the treatment of autoimmune and inflammatory diseases. Furthermore, widespread adoption of cost-efficient biosimilar monoclonal antibodies by medical practitioners and oncologists is also providing a boost to the market growth.

With technological advancements in gene sequencing and target gene selection, these antibodies can be modified to have similar properties to that of a pharmaceutical drug. They have the same efficiency but are available at reduced prices than the original medicine, which aids in enhancing the cost-efficiency of the treatment, thereby contributing to the increasing demand for the product across the globe.

Other factors, including rising preference for personalized medicines, extensive research and development (R&D) activities and significant improvements in the healthcare infrastructure, are projected to drive the market further.

The competitive landscape of the industry has also been examined with some of the key players being AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Genmab A/S, GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Seattle Genetics Inc., Spectrum Pharmaceuticals Inc., etc.

Key Questions Answered

• How has the global cancer monoclonal antibodies market performed so far and how will it perform in the coming years?
• What are the key regional markets?
• What is the breakup of the market based on the antibody type?
• What is the breakup of the market based on the medication type?
• What is the breakup of the market based on the application?
• What is the breakup of the market based on the end-user?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global cancer monoclonal antibodies market and who are the key players?
• What is the degree of competition in the industry?

Key Topics Covered

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Cancer Monoclonal Antibodies Market
5.1 Market Overview
5.2 Market Performance
5.3 Market Forecast

6 Market Breakup by Antibody Type
6.1 Murine Antibodies
6.2 Chimeric Antibodies
6.3 Humanized Antibodies
6.4 Others

7 Market Breakup by Medication Type
7.1 Bevacizumab (Avastin)
7.2 Rituximab (Rituxan)
7.3 Trastuzumab (Herceptin)
7.4 Cetuximab (Erbitux)
7.5 Panitumumab (Vectibix)
7.6 Others

8 Market Breakup by Application
8.1 Breast Cancer
8.2 Blood Cancer
8.3 Liver Cancer
8.4 Brain Cancer
8.5 Colorectal Cancer
8.6 Others

9 Market Breakup by End-user
9.1 Hospitals and Clinics
9.2 Pharmacies
9.3 Research Laboratories
9.4 Others

10 Market Breakup by Region
10.1 North America
10.2 Asia Pacific
10.3 Europe
10.4 Latin America
10.5 Middle East and Africa

11 SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players

• AbbVie Inc.
• Amgen Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Genmab A/S
• GlaxoSmithKline Plc.
• Johnson & Johnson
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Roche Holding AG
• Seattle Genetics Inc.
• Spectrum Pharmaceuticals Inc.

For more information about this report visit https://www.researchandmarkets.com/r/z0nyqc

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com